HONG KONG – China-based ophthalmology startup Ocumension Therapeutics Ltd. has inked a deal for potentially €36.25 million (US$41.35 million) to develop and commercialize French counterpart Nicox SA's NCX-470 in the Chinese mainland, Hong Kong, Macau and Taiwan. NCX-470 is a monoclonal antibody (MAb) for treating open-angle glaucoma and ocular hypertension.
HONG KONG – China-based ophthalmology startup Ocumension Therapeutics Ltd. has inked a deal for potentially €36.25 million (US$41.35 million) to develop and commercialize French counterpart Nicox SA's NCX470 in the Chinese mainland, Hong Kong, Macau and Taiwan.
HONG KONG – China's Bio-Thera Solutions Ltd. has launched the phase I trial of BAT-4306F, an antibody-dependent cellular cytotoxicity (ADCC)-enhanced monoclonal antibody (MAb) that seeks to treat relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma patients.
HONG KONG – South Korean tech giant LG Corp.'s life sciences arm, LG Chem Ltd., has entered an agreement to develop and commercialize Avacta Group plc's multiple affimer candidates to treat inflammatory disorders and oncology.
HONG KONG – South Korean tech giant LG Corp.'s life sciences arm, LG Chem Ltd., has entered an agreement to develop and commercialize Avacta Group plc's multiple affimer candidates to treat inflammatory disorders and oncology.
HONG KONG – China's Bio-Thera Solutions Ltd. has launched the phase I trial of BAT-4306F, an antibody-dependent cellular cytotoxicity (ADCC)-enhanced monoclonal antibody (MAb) that seeks to treat relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma patients.
HONG KONG – Jiankui He, the Chinese scientist under the spotlight following his claim of the first gene editing use in human embryos, apologized for what he called the unexpected leak of information and defended his controversial trial during the Second International Summit on Human Genome Editing.
HONG KONG – Jiankui He, the Chinese scientist under the spotlight following his claim of the first gene editing use in human embryos, apologized for what he called the unexpected leak of information and defended his controversial trial during the Second International Summit on Human Genome Editing.
